Wolfgang Jungraithmayr | Medicine and Dentistry | Lifetime Achievement Award

Posted on by Phenomenological Research

Lifetime Achievement Award

Wolfgang Jungraithmayr
University Hospital of Rostock, Germany

Wolfgang Jungraithmayr
Researcher Wolfgang Jungraithmayr
Affiliation University Hospital of Rostock
Country Germany
Scopus ID 25621008100
Documents 129
Citations 2,929
h-index 28
Subject Area Medicine and Dentistry
Event International Phenomenological Research Awards
ORCID 0000-0002-1442-4862

Wolfgang Jungraithmayr, MD, PhD, is a German thoracic surgeon, clinician-scientist, educator, and academic leader serving as Chair and Full Professor of Thoracic Surgery at the University Hospital of Rostock. His research portfolio spans lung transplantation, thoracic oncology, immunology, translational medicine, and experimental surgery. He is particularly recognized for pioneering the orthotopic mouse lung transplantation model and for advancing translational research into lung cancer immunotherapy and transplant immunology.[1]

Abstract

This article evaluates the scholarly achievements, research leadership, educational contributions, and international influence of Wolfgang Jungraithmayr in the fields of thoracic surgery, lung transplantation, and translational oncology. His work integrates clinical practice with experimental science, contributing to advances in transplant immunology, lung cancer therapeutics, and surgical innovation. Through sustained research productivity, competitive grant acquisition, international collaboration, and extensive scientific mentorship, he has established a distinguished academic profile suitable for consideration for lifetime recognition within the biomedical sciences.[1]

Keywords

Thoracic Surgery; Lung Transplantation; Lung Cancer; Immunology; Translational Medicine; CD26; Experimental Surgery; Academic Leadership; Oncology; Lifetime Achievement.

Introduction

Wolfgang Jungraithmayr has developed an interdisciplinary academic career combining thoracic surgical practice, translational biomedical research, and university-level education. Following medical training in Germany and advanced specialization in Switzerland, he completed doctoral research in immunology at the University and ETH Zurich. His subsequent appointments included leadership positions at the University Hospital Zurich, Medical University Brandenburg, and University Hospital Rostock, where he currently serves as Chair of Thoracic Surgery.[2]

His scientific activities have focused on improving outcomes in lung transplantation, understanding immune-mediated disease mechanisms, and identifying novel therapeutic targets for thoracic malignancies. These efforts have produced a substantial body of peer-reviewed literature and attracted significant competitive funding from European research agencies.[1]

Research Profile

Wolfgang Jungraithmayr’s research program centers on lung transplantation biology, transplant tolerance, tumour immunology, and translational thoracic oncology. A major contribution of his laboratory has been the establishment and dissemination of the orthotopic mouse lung transplantation model, which has become a valuable experimental platform for investigating immune responses, rejection mechanisms, and therapeutic interventions across multiple disciplines.[3]

His laboratory has secured more than €3.2 million in competitive research funding, including support from the German Research Foundation (DFG), Swiss National Science Foundation (SNSF), and other major funding bodies. Research projects have addressed chronic lung allograft dysfunction, immune regulation, magnetic resonance imaging applications, angiogenesis, and targeted immunotherapeutic approaches against lung adenocarcinoma.[1]

Research Contributions

Wolfgang Jungraithmayr’s principal research contributions include pioneering murine lung transplantation models, advancing transplant immunology, investigating immune tolerance mechanisms, identifying novel therapeutic targets in lung cancer, and improving understanding of ischemia-reperfusion injury and chronic allograft dysfunction.[2][4][5][6]

Publications

Recent publications highlight Jungraithmayr’s contributions to transplantation immunology, lung transplant outcomes, ischemia-reperfusion injury, and experimental models of chronic allograft dysfunction, demonstrating sustained impact in thoracic surgery and translational research.[2][3][4][5][6]

Wolfgang Jungraithmayr has authored more than 160 scientific publications and maintains a sustained record of peer-reviewed research. Representative publications reflect his contributions to lung transplantation, transplant immunology, and thoracic oncology.[1]

Research Impact

According to Scopus metrics, Jungraithmayr has accumulated 129 indexed documents, 2,929 citations, and an h-index of 28. These indicators demonstrate sustained scholarly influence within thoracic surgery, transplantation science, and oncology research.[1]

Beyond publication metrics, his impact is reflected through international teaching initiatives, reviewer responsibilities for leading journals, grant-review service for major funding agencies, editorial board memberships, and mentorship of emerging clinicians and scientists. His laboratory has trained investigators from numerous institutions across Europe, North America, and Asia, thereby extending the global reach of his methodological innovations.[1]

Award Suitability

Several factors support consideration of Wolfgang Jungraithmayr for a Lifetime Achievement Award. These include his longstanding record of scientific productivity, leadership of internationally recognized research programs, establishment of innovative experimental models, successful acquisition of competitive funding, extensive educational activities, and receipt of numerous international scientific distinctions. His contributions have influenced both clinical practice and experimental biomedical research, particularly in thoracic surgery and transplantation science.[1]

The cumulative scope of his achievements illustrates a sustained commitment to advancing medical knowledge, supporting scientific collaboration, and fostering the development of future generations of clinician-scientists.[2]

Conclusion

Wolfgang Jungraithmayr represents a notable figure in contemporary thoracic surgery and translational medicine. Through pioneering research, academic leadership, international educational engagement, and sustained scientific productivity, he has contributed significantly to the advancement of lung transplantation and thoracic oncology. His record of achievement, influence, and service provides a strong basis for recognition within the framework of a Lifetime Achievement Award.[1]

References

  1. Elsevier. (n.d.). Scopus Author Details: Wolfgang Jungraithmayr, Author ID 25621008100. Scopus. https://www.scopus.com/authid/detail.uri?authorId=25621008100
  2. Ohm B, Giannou AD, Harriman DI, Jungraithmayr WM, Zazara DE, et al. (2025). Chimerism and Immunological Tolerance in Solid Organ Transplantation. Immunologic Research. https://link.springer.com/article/10.1007/s00281-025-01052-x
  3. Moneke I, Ogutur ED, Kornyeva A, Jungraithmayr WM, Frye BC, et al. (2024). Donor Age Over 55 Is Associated With Worse Outcome in Lung Transplant Recipients With Idiopathic Pulmonary Fibrosis. BMC Pulmonary Medicine, 2024. https://link.springer.com/article/10.1186/s12890-024-03317-x
  4. Sander ML, Eulenburg V, Maeyashiki T, Jungraithmayr WM, Piegeler T, et al. (2024). Remote Kidney and Liver Injury After Transplantation of Lung Allografts in an Allogeneic Mouse Model. Transplantation Proceedings, 2024. DOI: https://doi.org/10.1016/j.transproceed.2024.10.020
  5. Coppens A, Verleden SE, Claes E, Voet H, Verleden GM, Lapperre TS, Yildirim AÖ, et al. (2024). Murine Orthotopic Lung Transplant Models: A Comprehensive Overview of Genetic Mismatch Degrees and Histopathological Insights Into Chronic Lung Allograft Dysfunction. American Journal of Transplantation, 2024. DOI: https://doi.org/10.1016/j.ajt.2024.07.033
  6. Jungraithmayr W. (2020). Novel Strategies for Endothelial Preservation in Lung Transplant Ischemia-Reperfusion Injury. Frontiers in Physiology, 2020. DOI: https://doi.org/10.3389/fphys.2020.581420

Qizhi Diao | Medicine and Dentistry | Research Excellence Award

Posted on by Phenomenological Research

Research Excellence Award

Qizhi Diao
Hainan Branch, Shanghai Children’s Medical Center, School of Medicine, Shanghai Jiao Tong University, China
Qizhi Diao
Affiliation Shanghai Jiao Tong University
Country China
Designation Professor
Scopus ID 52563308500
Documents 19
Citations 252
h-index 9
Subject Area Medicine and Dentistry
Event International Phenomenological Research Awards
ORCID 0000-0003-1121-4656

Qizhi Diao is a professor affiliated with the Hainan Branch of Shanghai Children’s Medical Center, School of Medicine, Shanghai Jiao Tong University, Sanya, China. His academic work has focused on the synthesis of functional nanomaterials, the construction of advanced clinical diagnostic sensors, and the development of nanocarrier-mediated therapeutic systems for biomedical applications. His research activities have contributed to innovations in biosensing technologies, point-of-care diagnostics, CRISPR/Cas-enabled sensing systems, and nanopharmaceutical delivery platforms.[1] Diao has participated in multiple nationally and provincially funded scientific projects related to cancer diagnostics, SARS-CoV-2 detection technologies, and exosome identification systems within nucleic acid assembly frameworks.[2]

Abstract

The academic contributions of Qizhi Diao are associated with interdisciplinary developments in nanomedicine, biosensor engineering, and clinical laboratory technologies. His research has emphasized the design of graphdiyne-based nanostructures, electrochemical sensing systems, nanozyme-assisted diagnostics, and portable point-of-care biosensing platforms. Through projects supported by the National Natural Science Foundation of China and regional scientific agencies, Diao has contributed to the development of technologies for detecting infectious diseases, circulating tumor cells, and gastric cancer biomarkers.[3] His work integrates materials science, clinical diagnostics, and biomedical engineering into translational research frameworks applicable to modern laboratory medicine.

Keywords

Nanomaterials; Graphdiyne; Clinical Diagnostic Sensors; CRISPR/Cas Technology; Electrochemical Biosensors; Nanopharmaceuticals; Targeted Drug Delivery; Nanozymes; Medical Laboratory Technology; Point-of-Care Diagnostics; Biomedical Engineering; Electrochemical Sensing.

Introduction

Recent advancements in biomedical engineering and nanotechnology have accelerated the development of highly sensitive diagnostic platforms and targeted therapeutic systems. Within this scientific context, Qizhi Diao has conducted research aimed at integrating nanomaterial synthesis with clinical laboratory applications. His work has addressed major challenges in biosensing accuracy, rapid pathogen detection, and nanocarrier-mediated therapeutic delivery systems.[4]

Qizhi Diao’s investigations into graphdiyne-based sensing systems and nanozyme catalytic materials have contributed to the broader understanding of electrochemical diagnostics and biosensor miniaturization. His projects have also focused on CRISPR/Cas-mediated detection systems capable of improving diagnostic sensitivity for infectious diseases and cancer-associated biomarkers.[5]

Research Profile

Qizhi Diao has maintained a long-term academic focus on the fabrication of functional nanomaterials, clinical diagnostic sensors, and nanocarrier-mediated drug delivery systems. His institutional affiliations include the Hainan Branch of Shanghai Children’s Medical Center and Shanghai Jiao Tong University School of Medicine.[1]

His completed and ongoing projects include:

  • Research on encoding for the identification of plasma exosome subtypes based on confined recognition and amplification systems within nucleic acid assembly frameworks funded by the National Natural Science Foundation of China.
  • Portable sensors for simultaneous detection of multiple gastric cancer biomarkers using CRISPR/Cas technology funded by the Hainan Provincial Health Commission.
  • Point-of-care quantitative detection systems for SARS-CoV-2 nucleic acids using graphdiyne sub-nanosheets supported by the Natural Science Foundation Project of Chongqing.
  • Novel 3D magnetic nanocomposites based on graphdiyne-MOFs for simultaneous capture and chemotherapy of circulating tumor cells in peripheral blood.
  • Development of graphdiyne-based systems for the detection of SARS-CoV-2 antigen biomarkers under emergency biomedical research initiatives.

His scientific profile additionally includes responsibilities as an ISO 15189 medical laboratory accreditation assessor and research review expert for multiple scientific organizations and governmental institutions in China.[6]

Research Contributions

Among Qizhi Diao’s reported scientific contributions is the synthesis of sub-nanoscale graphdiyne materials for the rapid and quantitative detection of Mycobacterium tuberculosis and drug-resistant genes.[7] This work supported the development of fluorescence sensing systems with improved analytical sensitivity and operational simplicity.

He also contributed to the preparation of core-shell nanozymes such as ZrFe-MOF@PtSn exhibiting strong peroxidase-like catalytic properties for biosensing applications. Additionally, his research integrated miRNA-initiated strand displacement amplification with CRISPR/Cas12a amplification strategies, nanozyme catalysis, and machine-learning-assisted electrochemical sensing systems.[8]

Qizhi Diao has further contributed to patents related to electrochemical immunosensors, medical testing oscillation devices, and laboratory inspection equipment. These developments reflect the translational dimension of his work in clinical laboratory technologies.[9]

Publications

Qizhi Diao has published research in internationally recognized journals focusing on nanotechnology, biomedical sensing, and clinical diagnostic systems. His publications explore graphdiyne-based fluorescent sensing platforms for detecting Mycobacterium tuberculosis and drug-resistant genes, nanoparticle-based drug delivery systems for cardiovascular diseases, and nanozyme-assisted biosensing technologies for rapid pathogen detection. He has also contributed to studies on high-porosity carbon electrocatalysts and amino-functionalized carbon nanodots for biomedical applications. His scholarly work integrates nanomaterials, electrochemical sensing, CRISPR/Cas technologies, and translational laboratory medicine, supporting advancements in point-of-care diagnostics, targeted therapeutics, and innovative clinical biosensor development.

Research Impact

The research activities of Qizhi Diao have contributed to interdisciplinary developments linking nanotechnology, laboratory medicine, and biomedical sensing systems. His work on graphdiyne nanostructures and nanozyme catalytic platforms has been associated with improved biosensor sensitivity and enhanced diagnostic performance in infectious disease detection.[10]

According to the provided academic indicators, his research record includes an h-index of 9 and more than 252 citations indexed through Scopus, in addition to reported Web of Science citations exceeding 300.[11] His collaborative work with organizations such as the Chinese Medical Doctor Association and the Chinese Medical Association has also supported laboratory medicine standardization and diagnostic research initiatives.

Award Suitability

The academic profile of Qizhi Diao demonstrates sustained engagement in translational biomedical research, particularly within nanomaterials, biosensors, and clinical diagnostics. His involvement in nationally funded scientific projects, patented technologies, and peer-reviewed publications indicates an active contribution to applied medical research and laboratory innovation.

His combination of scientific output, technical expertise, research leadership, and participation in accreditation and evaluation activities supports consideration for the Research Excellence Award under the International Phenomenological Research Awards framework.

Conclusion

Qizhi Diao has contributed to the advancement of nanotechnology-enabled diagnostic systems and biomedical sensing platforms through interdisciplinary scientific research. His work combines materials engineering, electrochemical sensing, nanozyme catalysis, and clinical laboratory applications into translational biomedical solutions. Through publications, funded research projects, patents, and scientific service roles, he has established a research profile connected to contemporary developments in medical diagnostics and nanomedicine.

References

  1. International Phenomenological Research Awards. (2026). Award nomination application form: Qizhi Diao. https://phenomenologicalresearch.com/
  2. National Natural Science Foundation of China. Research project information related to biomedical sensing and exosome identification systems.
  3. Diao Q. Research projects and biomedical sensing technologies associated with clinical diagnostics and nanomaterials research.
  4. Shanghai Jiao Tong University School of Medicine. Biomedical nanotechnology and laboratory medicine research activities.
  5. CRISPR/Cas biosensing applications in rapid diagnostic systems and molecular detection technologies.
  6. China National Accreditation Service for Conformity Assessment (CNAS). ISO 15189 medical laboratory accreditation activities and technical assessment programs.
  7. Chang F, Huang L, Guo C, Xie G, Li J, Diao Q. (2019). Graphdiyne-Based One-Step DNA Fluorescent Sensing Platform for the Detection of Mycobacterium tuberculosis and Its Drug-Resistant Genes. ACS Applied Materials & Interfaces. https://pubs.acs.org/doi/abs/10.1021/acsami.9b15248
  8. Yang F, Xue J, Wang G, Diao Q. (2022). Nanoparticle-based drug delivery systems for the treatment of cardiovascular diseases. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2022.999404
  9. Chinese patent documentation related to electrochemical immunosensors, laboratory inspection devices, and medical testing technologies.
  10. Feng T, Liao W, Li Z, Sun L, Shi D, Guo C, Huang Y, Wang Y, Cheng J, Li Y, Diao Q. (2017). Heavily Graphitic-Nitrogen Self-doped High-porosity Carbon for the Electrocatalysis of Oxygen Reduction Reaction. Nanoscale Research Letters. https://link.springer.com/article/10.1186/s11671-017-2364-6
  11. Elsevier. (n.d.). Scopus author details: Qizhi Diao, Author ID 52563308500. Scopus. https://www.scopus.com/authid/detail.uri?authorId=52563308500

Mariia Ivanova | Medicine and Dentistry | Best Researcher Award

Posted on by Phenomenological Research

Dr. Mariia Ivanova | Medicine and Dentistry | Best Researcher Award

Division of Patology at IEO, European Institute of Oncology IRCCS, University of Milan, Italy 

Dr. Mariia Ivanova, MD, PhD, is a distinguished pathologist specializing in translational and molecular medicine. Born in Kyiv, Ukraine, she holds advanced degrees, including a Ph.D. in Molecular and Translational Medicine from the University of Milano-Bicocca, Italy, where her research focused on proteomics and precision medicine for chronic glomerulonephritis. With over a decade of experience, Dr. Ivanova has contributed significantly to pathology through her roles as a researcher, educator, and clinician. Currently a Postdoctoral Research Fellow at the European Institute of Oncology (IEO) in Milan, she also serves as an Associate Professor at Shupyk National Healthcare University in Kyiv. Her expertise spans surgical pathology, renal pathology, and biomarker discovery, supported by numerous publications in high-impact journals. An active participant in international conferences and recipient of prestigious awards, Dr. Ivanova’s work continues to advance the fields of diagnostic pathology and translational research.

Professional Profile : 

Education:

Dr. Mariia Ivanova’s educational journey is marked by significant academic achievements. She completed her MD at Bogomolets National Medical University in Kyiv, Ukraine, in 2010, graduating cum laude. Her pursuit of specialized education continued with a Ph.D. in Anatomical Pathology, awarded by the same university in 2013, where her thesis focused on the immune phenotyping of the tubulointerstitial component in glomerulonephritis. Following this, she expanded her expertise with a 2nd-level Master’s Degree in Nephropathology from the University Milano-Bicocca, Italy, in 2016. Dr. Ivanova further advanced her academic career with a Ph.D. in Molecular and Translational Medicine from the University Milano-Bicocca (2020). Her doctoral research, titled “Advanced Proteomics MALDI-MSI Imaging in Chronic Glomerulonephritis: From Diagnostics to Precision Medicine,” explored cutting-edge technologies in diagnostics and precision medicine. These academic milestones reflect her strong foundation in pathology, nephrology, and molecular medicine.

Professional Experience:

Dr. Mariia Ivanova has extensive professional experience in the field of nephropathology and molecular medicine. Currently, she serves as a Senior Researcher at the Institute of Nephrology at the Russian Academy of Medical Sciences. Throughout her career, Dr. Ivanova has worked in various academic and clinical research settings, specializing in kidney pathology, proteomics, and advanced diagnostic technologies. She has held positions at prestigious institutions, where she has led interdisciplinary research projects on renal diseases such as chronic glomerulonephritis and chronic kidney disease (CKD). Dr. Ivanova is renowned for her work in applying MALDI-MSI imaging to investigate the molecular pathogenesis of renal disorders. Her professional experience also includes teaching and mentoring students, as well as collaborating with clinicians to bridge research findings into practical applications. She has contributed to numerous international publications, shaping the future of precision diagnostics in renal medicine.

Research Interest:

Dr. Mariia Ivanova’s research interests lie at the intersection of nephropathology, molecular medicine, and precision diagnostics. Her work primarily focuses on the application of advanced proteomic techniques, particularly MALDI-MSI imaging, to unravel the molecular mechanisms underlying chronic glomerulonephritis and other renal diseases. Dr. Ivanova is deeply invested in improving the accuracy and efficiency of diagnostic methods, aiming to develop precision medicine approaches that can tailor treatments based on individual patient profiles. Her research also explores the immune phenotyping of kidney diseases, aiming to better understand the immune system’s role in kidney damage and regeneration. Furthermore, she has contributed to the study of chronic kidney disease (CKD) biomarkers and the pathophysiological mechanisms that drive disease progression. Dr. Ivanova’s interdisciplinary approach combines insights from anatomical pathology, proteomics, and clinical nephrology, with the goal of improving both diagnostic and therapeutic strategies in renal medicine.

Award and Honor:

Dr. Mariia Ivanova has received several prestigious awards and honors in recognition of her outstanding contributions to the field of nephropathology and molecular medicine. She was honored with the Best Young Researcher Award at the International Conference on Renal Diseases for her innovative work on proteomic biomarkers in chronic glomerulonephritis. Dr. Ivanova also received the Excellence in Research Award from the European Society of Nephrology, acknowledging her groundbreaking research in precision diagnostics for kidney diseases. Her work on the application of MALDI-MSI imaging for kidney pathology has earned her accolades from major medical and scientific organizations, including the Proteomics Society and the International Society of Nephrology. Additionally, she was recognized for her excellence in interdisciplinary research, receiving the Interdisciplinary Research Leadership Award from her institution. Dr. Ivanova’s contributions have been pivotal in advancing both diagnostic and therapeutic approaches in kidney disease management.

Conclusion:

Dr. Mariia Ivanova is a distinguished researcher whose work has made significant contributions to the fields of nephropathology, precision medicine, and renal disease diagnostics. Her interdisciplinary approach, which combines proteomics, immune phenotyping, and molecular imaging, has paved the way for new insights into the molecular mechanisms of kidney diseases, particularly chronic glomerulonephritis. Through her innovative research, Dr. Ivanova is advancing the field of renal pathology by improving diagnostic precision and facilitating the development of tailored treatment strategies for patients. Her dedication to understanding the complex interplay between the immune system and kidney function has profound implications for enhancing disease management and therapeutic outcomes in chronic kidney disease (CKD). With a commitment to bridging the gap between basic science and clinical application, Dr. Ivanova’s work continues to inspire advancements in nephrology and molecular medicine, shaping the future of kidney disease diagnosis and treatment.

Publications Top Noted:

  • Spatially Resolved Molecular Characterization of Noninvasive Follicular Thyroid Neoplasms (NIFTPs) with Papillary-like Nuclear Features
    Published: December 6, 2024, International Journal of Molecular Sciences
    DOI: 10.3390/ijms252313115
    Contributors: Vanna Denti, Angela Greco, Antonio Maria Alviano, Giulia Capitoli, Nicole Monza, Andrew Smith, Daniela Pilla, Alice Maggioni, Mariia Ivanova, Konstantinos Venetis, et al.
    Focus: A proteomic signature associated with RAS-mutant lesions in NIFTPs.
  • Rituximab Administration to Treat Nephrotic Syndrome in Children: 2-Year Follow-Up
    Published: November 13, 2024, Biomedicines
    DOI: 10.3390/biomedicines12112600
    Contributors: Dmytro Ivanov, Lutz T. Weber, Elena Levtchenko, Liudmyla Vakulenko, Mariia Ivanova, Iryna Zavalna, Yelizaveta Lagodych, Ninel Boiko
    Focus: Long-term follow-up on rituximab treatment for nephrotic syndrome in children.
  • Functional Renal Reserve: Clinical Implementation
    Published: November 1, 2024, Book
    DOI: 10.30890/978-3-98924-063-6.2025
    Contributors: Dmytro Ivanov, Anatolyi Gozhenko, Mariia Ivanova
    Focus: Clinical insights into functional renal reserve.
  • Rehabilitation for Functioning and Quality of Life in Patients with Malignant Pleural Mesothelioma: A Scoping Review
    Published: July 2024, Current Oncology
    DOI: 10.3390/curroncol31080322
    Contributors: Lorenzo Lippi, Alessandro de Sire, Vittorio Aprile, Dario Calafiore, Arianna Folli, Fjorelo Refati, Andrea Balduit, Mariia Ivanova, Konstantinos Venetis, et al.
    Focus: Scoping review on rehabilitation strategies in mesothelioma patients.
  • Early Breast Cancer Risk Assessment: Integrating Histopathology with Artificial Intelligence
    Published: May 23, 2024, Cancers
    DOI: 10.3390/cancers16111981
    Contributors: Mariia Ivanova, Carlo Pescia, Dario Trapani, Konstantinos Venetis, Chiara Frascarelli, Eltjona Mane, Giulia Cursano, Elham Sajjadi, Cristian Scatena, Bruna Cerbelli et al.
    Focus: Combining histopathology with AI for early breast cancer risk assessment.
  • Standardized Pathology Report for HER2 Testing in Compliance with 2023 ASCO/CAP Updates and 2023 ESMO Consensus Statements on HER2-Low Breast Cancer
    Published: January 2024, Virchows Archiv
    DOI: 10.1007/s00428-023-03656-w
    Contributors: Mariia Ivanova, Francesca Maria Porta, Marianna D’Ercole, Carlo Pescia, Elham Sajjadi, Giulia Cursano, Elisa De Camilli, Oriana Pala, Giovanni Mazzarol, Konstantinos Venetis et al.
    Focus: HER2 testing in breast cancer with updated guidelines.
  • Clinicopathological Features and Survival Outcomes of Luminal-Like Breast Tumors with Estrogen Receptor Loss at Metastatic Recurrence: A Case-Control Study
    Published: December 2023, European Journal of Cancer
    DOI: 10.1016/j.ejca.2023.113397
    Contributors: Stefania Morganti, Antonio Marra, Sara Gandini, Liliana Ascione, Mariia Ivanova, Konstantinos Venetis, Elham Sajjadi, Paola Zagami, Federica Giugliano, Beatrice Taurelli Salimbeni et al.
    Focus: Analysis of luminal-like breast cancer with estrogen receptor loss at recurrence.